Median Time to Disease Progression From Day 1 Until First Documented Disease Progression or Date of Death (Whichever Occurred First) [clinicaltrials_resource:cdc4de78ea31f70cb22fc87079ca0e35]
Assessed by Response Evaluation Criteria In Solid Tumor (RECIST criteria). Progression is defined as a measureable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions since baseline.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Median Time to Disease Progression From Day 1 Until First Documented Disease Progression or Date of Death (Whichever Occurred First) [clinicaltrials_resource:cdc4de78ea31f70cb22fc87079ca0e35]
Assessed by Response Evaluation Criteria In Solid Tumor (RECIST criteria). Progression is defined as a measureable increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions since baseline.
Bio2RDF identifier
cdc4de78ea31f70cb22fc87079ca0e35
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:cdc4de78ea31f70cb22fc87079ca0e35
measure [clinicaltrials_vocabulary:measure]
Median Time to Disease Progression
time frame [clinicaltrials_vocabulary:time-frame]
From Day 1 Until First Documen ...... ath (Whichever Occurred First)
description
Assessed by Response Evaluatio ...... of new lesions since baseline.
identifier
clinicaltrials_resource:cdc4de78ea31f70cb22fc87079ca0e35
title
Median Time to Disease Progres ...... ath (Whichever Occurred First)
@en
type
label
Median Time to Disease Progres ...... 4de78ea31f70cb22fc87079ca0e35]
@en